BEIJING, February 19, 2024 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nomination period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with the option to acquire selected antibo
(Bloomberg) Gilead Sciences Inc.’s Trodelvy failed to significantly improve survival in a trial of patients with advanced lung cancer, a blow to the targeted treatment that’s in one of the most promising classes in oncology.Most Read from BloombergFlorida Governor DeSantis Drops Out of 2024 Race, Endorses TrumpHong Kong Stocks at 36% Discount Show True Depth of China GloomMorgan Stanley, JPMorgan Say Buy the Dip After Treasury RoutGloom Over China Assets Is Spreading Beyond Battered StocksHed
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it.